OSLO/LONDON, 19 May 2022: EXACT Therapeutics AS ("EXACT-Tx", Euronext Growth:
EXTX), a clinical stage biopharmaceutical company with a mission to enhance the
therapeutic efficacy of medicines through ultrasound-mediated drug delivery,
today announces that its Board Member, Dr. Jean-Claude Provost will step down
with immediate effect.
Dr. Provost has taken on a new role as interim CMO of Lantheus Holdings (NASDAQ:
LNTH). As this could represent a conflict of interest with his current Board
appointment to EXACT-Tx, the Company and Dr. Provost have agreed that he will
resign from the Board of Directors with immediate effect. The Nomination
Committee is recommending that he is not replaced at the AGM in June.
On behalf of the shareholders, the Board thanks Dr. Provost for his support and
contribution to EXACT-Tx over the last few years.
For more information, please contact:
Masha StrØmme, Executive Chair
Dominic Moreland, CFO
EXACT-Tx is a Norwegian clinical-stage precision health company developing a
technology platform for targeted therapeutic enhancement - Acoustic Cluster
Therapy (ACT®). ACT® is a proprietary formulation of microclusters (PS101)
activated by ultrasound for enhanced drug targeting deployed in multiple
indications to enhance the therapeutic efficacy of medicines through the use of
ultrasound-mediated drug delivery, for patients across multiple diseases.
Forward looking statements
This announcement and any materials distributed in connection with this
announcement may contain certain forward-looking statements. By their nature,
forward-looking statements involve risk and uncertainty because they reflect the
Company's current expectations and assumptions as to future events and
circumstances that may not prove accurate. A number of material factors could
cause actual results and developments to differ materially from those expressed
or implied by this forward-looking statement.